A phase 3 randomized trial of 628 postmenopausal patients found that elinzanetant, taken once daily, reduced moderate to severe vasomotor symptoms by 74% at 12 weeks compared with 47% with placebo. Improvements were seen as early as week 1 and sustained through 1 year. Sleep disturbance and menopause-related quality-of-life scores also improved. Adverse events, including somnolence, fatigue, and headache, were more frequent with elinzanetant but generally mild. No hepatotoxicity, endometrial abnormalities, or bone loss were observed. Researchers noted limited representation of Asian and Pacific Islander patients and exclusion of those with recent cancer histories.

Source: JAMA Internal Medicine